Overview
- The application seeks authorization for a formulation nearly three times the current maximum Wegovy dose.
- Longer-term trials showed average weight loss of 20.7% on the higher dose versus 15% on the current regimen.
- Shares of Novo Nordisk rose about 3.5% intraday following the filing.
- The move comes days after a failed Alzheimer’s trial that had weighed on the stock.
- Analysts suggest potential rivals such as Viking Therapeutics could enter the market by 2029 as Novo advances additional weight-management candidates.